The nephrotoxicity of new immunotherapies
Authors:
- 8 May 2019
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 12 (6) , 513-521
Abstract
Introduction: Advanced cancers that did not respond to chemotherapy were once a death sentence, but now there are newer therapies utilizing the patient’s own immune system to fight cancer that are proving effective in chemotherapy-refractory malignancies. However, this success against cancer cells may be accompanied by immune-related adverse events that can affect the kidneys. Areas Covered: Using Medline and Scopus, we compiled all publications pertaining to ICPI and CAR T-cell therapy through February 2019. The focus of this review is discussion of two new cancer therapies, immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy, with attention to the reported kidney-related adverse effects. Expert Opinion: Autoimmunity is repressed by molecular pathways that inhibit T-cell activation against selected antigens. These self-protective mechanisms have been appropriated by tumor cells as a means of evading immune detection and destruction. New immunotherapies such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy incite an aggressive immune response directed against tumor cells. This unrestrained activation of the immune system may result in kidney injury via multiple mechanisms.Keywords
This publication has 92 references indexed in Scilit:
- Generation of Suicide Gene-Modified Chimeric Antigen Receptor-Redirected T-Cells for Cancer Immunotherapy2018
- Cancer Immunotherapy Using CAR‐T Cells: From the Research Bench to the Assembly LineBiotechnology Journal, 2017
- PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patientsBreast Cancer Research and Treatment, 2017
- T cell recognition of HLA‐A2 restricted tumor antigens is impaired by the oncogene HER2International Journal of Cancer, 2010
- HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic miceCancer Immunology, Immunotherapy, 2008
- Molecular mechanisms of MHC class I abnormalities and APM components in human tumorsCancer Immunology, Immunotherapy, 2008
- CTLA‐4 disrupts ZAP70 microcluster formation with reduced T cell/APC dwell times and calcium mobilizationEuropean Journal of Immunology, 2007
- Targeting of tumor cells by lymphocytes engineered to express chimeric receptor genesCancer Immunology, Immunotherapy, 2004
- MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinomaInternational Journal of Cancer, 2003
- MHC class I‐deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM componentsInternational Journal of Cancer, 2003